{"id": "cme_001", "displayed_text": "Recent advances in CAR-T cell therapy have shown promising results in treating B-cell lymphomas. The FDA-approved tisagenlecleucel has demonstrated overall response rates of 52% in adult patients with relapsed or refractory large B-cell lymphoma.", "label_annotations": {"verification": {"\u274c Incorrect": "2"}, "corrected_specialty": {"text_box": "test"}, "state_verification": {"\u2705 Correct": "1"}, "corrected_state": {"text_box": "idk "}}, "span_annotations": {}, "behavioral_data": {"time_string": "Time spent: 0d 0h 1m 14s "}}
